<DOC>
	<DOCNO>NCT00690872</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving infusion person 's T lymphocytes treated laboratory may help body build effective immune response kill tumor cell . Giving combination chemotherapy together laboratory-treated T lymphocyte may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine carboplatin together laboratory-treated T lymphocytes work treat patient metastatic locally recurrent Epstein-Barr virus-positive nasopharyngeal cancer .</brief_summary>
	<brief_title>Gemcitabine Carboplatin Followed By Laboratory-Treated T Lymphocytes Treating Patients With Metastatic Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine progression-free survival ( PFS 1 ) patient metastatic locally recurrent Epstein-Barr virus ( EBV ) -positive nasopharyngeal carcinoma treat gemcitabine hydrochloride carboplatin follow EBV-specific cytotoxic T-lymphocytes ( CTL ) . Secondary - To determine progression-free survival ( PFS 2 ) patient immunotherapy portion study . - To determine clinical benefit rate EBV-specific CTL patient . - To determine tolerability EBV-specific CTL therapy patient . - To demonstrate persistence EBV-specific immune response patient . OUTLINE : Patients undergo collection peripheral blood mononuclear cell ( PBMC ) T cell purify , co-cultured irradiated autologous Epstein-Barr virus ( EBV ) -specific cytotoxic T-lymphocytes ( CTLs ) , expand vitro establishment cytotoxic T-cell line . - Chemotherapy : Patients receive gemcitabine hydrochloride IV 30 minute carboplatin IV 60 minute day 1 , 8 , 15 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . After completion course 2 , patient undergo evaluation response . Patients progressive disease proceed directly induction immunotherapy . Patients stable disease ( SD ) , partial response ( PR ) , complete response ( CR ) receive 2 additional course chemotherapy proceed induction immunotherapy . - Induction immunotherapy : Beginning 14-28 day completion chemotherapy , patient receive EBV-specific CTLs IV 1-10 minute day 1 14 . Six week second infusion , patient undergo evaluation response . Patients demonstrate clinical benefit ( i.e. , CR , PR , SD ) induction immunotherapy proceed maintenance immunotherapy . - Maintenance immunotherapy : Patients receive EBV-specific CTLs IV 1-10 minute . Treatment repeat every 1-3 month 4 course absence disease progression unacceptable toxicity . Patients undergo blood sample collection baseline prior course induction immunotherapy maintenance immunotherapy . Samples analyze EBV CTL frequency immune function assay ( i.e. , tetramer analysis , enzyme-linked immunospot , cytotoxic T-lymphocyte precursor assay ) ; specificity response cytotoxicity assay ( patient appropriate reagent available ) ; evaluation EBV DNA polymerase chain reaction . In addition , T-cells isolate blood sample fluorescence-activated cell sorter analysis extraction RNA . After completion study therapy , patient follow least every 2 month disease progression .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven nasopharyngeal carcinoma ( NPC ) WHO type 2/3 disease Metastatic locally recurrent disease EpsteinBarr virus ( EBV ) positive disease confirm situ hybridization assay PCR amplification EBVencoded RNA expression Radiologically measurable disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month ANC &gt; 1,200/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 3 time ULN Creatinine clearance ≥ 40 mL/min Corrected calcium normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent severe illness , include follow : Chronic obstructive pulmonary disease Ischemic heart disease Active congestive cardiac failure Active angina pectoris Uncontrolled arrhythmia Uncontrolled hypertension No concurrent severe infection HIV negative PRIOR CONCURRENT THERAPY : No one line prior chemotherapy metastatic disease No prior gemcitabine hydrochloride Prior platinum agent allow At least 1 month since prior investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
</DOC>